Literature DB >> 21951566

Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease.

Tessa Fayers1, Peter J Dolman.   

Abstract

AIM: To develop and test a user-friendly questionnaire for rapidly assessing quality of life (QOL) in thyroid eye disease (TED).
METHODS: A three-item questionnaire, the TED-QOL, was designed and compared to the 16-item Graves Ophthalmopathy (GO)-QOL and the nine-item GO-Quality of Life Scale (QLS). 100 patients with TED were administered all three questionnaires on two occasions. Results were compared to clinical severity scores (Vision, Inflammation, Strabismus, Appearance (VISA) classification). Main outcomes were construct and criterion validity, test-retest reliability, duration, comprehension and completion rates. TED-QOL correlated strongly with the other questionnaires for corresponding items (Pearson correlation: appearance 0.71, 0.62; functioning 0.69, 0.66; overall QOL 0.53). Test-retest analysis demonstrated good reliability for all three questionnaires (intraclass correlations: TED-QOL 0.81, 0.74, 0.87; GO-QOL 0.81, 0.82; GO-QLS 0.74, 0.86, 0.67). TED-QOL was significantly faster to complete (1.6 min vs GO-QOL 3.1 min, GO-QLS 2.7 min, p<0.0001) and had a higher completion rate (100% vs GO-QOL 78%, GO-QLS 94%). There was only moderate correlation between items on all three questionnaires and VISA scores.
CONCLUSION: The TED-QOL is rapid and easy to complete and analyse and has similar validity and reliability to longer questionnaires. All questionnaires showed only moderate correlation with disease severity, emphasising the discrepancy between objective and subjective assessments and the importance of measuring both.

Entities:  

Mesh:

Year:  2011        PMID: 21951566     DOI: 10.1136/bjophthalmol-2011-300487

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  Measuring quality of life in oculoplastic patients.

Authors:  Edward Ridyard; Clare Inkster
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

2.  Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy.

Authors:  Luigi Bartalena; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2020-09-21

Review 3.  Current and Emerging Treatment Strategies for Graves' Orbitopathy.

Authors:  Natalia Genere; Marius N Stan
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 4.  Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.

Authors:  Xueting Li; Senmao Li; Wanlin Fan; Alexander C Rokohl; Sitong Ju; Xiaojun Ju; Yongwei Guo; Ludwig M Heindl
Journal:  Int Ophthalmol       Date:  2022-10-22       Impact factor: 2.029

Review 5.  Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management.

Authors:  Jesús Barrio-Barrio; Alfonso L Sabater; Elvira Bonet-Farriol; Álvaro Velázquez-Villoria; Juan C Galofré
Journal:  J Ophthalmol       Date:  2015-08-17       Impact factor: 1.909

6.  Development and Validation of the Singapore Thyroid Eye Disease Quality of Life Questionnaire.

Authors:  Melissa H Y Wong; Eva Fenwick; Ai Tee Aw; Ecosse L Lamoureux; Lay Leng Seah
Journal:  Transl Vis Sci Technol       Date:  2018-10-01       Impact factor: 3.283

Review 7.  Thyroid disease-specific quality of life questionnaires - A systematic review.

Authors:  Verena Uslar; Caroline Becker; Dirk Weyhe; Navid Tabriz
Journal:  Endocrinol Diabetes Metab       Date:  2022-07-20

Review 8.  Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.

Authors:  Caroline Y Yu; Rebecca L Ford; Sara T Wester; Erin M Shriver
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

Review 9.  An overview of thyroid eye disease.

Authors:  Colm McAlinden
Journal:  Eye Vis (Lond)       Date:  2014-12-10

10.  Development and psychometric properties of the Thai Graves' ophthalmopathy quality of life (GO-QOL) questionnaire.

Authors:  Mingkwan Lumyongsatien; Benjama Keeratidamkerngsakul; Kanokrat Pornpanich; Sumalee Vangveeravong; Preamjit Saonanon; Damrong Wiwatwongwana; Pornchai Mahaisavariya; Orapan Aryasit; Krit Pongpirul
Journal:  J Patient Rep Outcomes       Date:  2019-12-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.